Evaluation of breast cancer treatment at a tertiary-level institution with Popular Health Insurance in Mexico;Evaluación del tratamiento del cáncer de mama en una institución del tercer nivel con el Seguro Popular, México

Revista de Investigacion Clinica

Volumn 64, Issue 1, 2012, Pages 9-16

  Arce Salinas, Claudia ^a   Lara Medina, Fernando Ulises ^a   Alvarado Miranda, Alberto ^a   Castañeda Soto, Noel ^a   Bargalló Rocha, Enrique ^a   Ramírez Ugalde, María Teresa ^a   Pérez Sánchez, Víctor ^a   Rivera, Lesbia ^a   Gambo Vignole, Carlos ^a   Santamaría Galicia, Julieta ^a   Nieves Casas, Rosa Isela ^a   Morán Muñoz, Héctor ^a   Mohar Betancourt, Alejandro ^b  

^a INSTITUTO NACIONAL DE CANCEROLOGÍA   (Mexico)

^b INSTITUTO DE INVESTIGACIONES BIOMÉDICAS   (Mexico)

Author keywords

Adjuvant chemotherapy; Breast cancer; Neoadjuvant chemotherapy; Seguro popular

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUOROURACIL; PACLITAXEL; TRASTUZUMAB;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; DISEASE FREE SURVIVAL; HEALTH INSURANCE; HUMAN; MAJOR CLINICAL STUDY; MEXICO; OVERALL SURVIVAL; TERTIARY HEALTH CARE; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DISEASE MANAGEMENT; DISEASE-FREE SURVIVAL; DOXORUBICIN; ESTROGENS; FEMALE; FLUOROURACIL; GENES, ERBB-2; HUMANS; INSURANCE, MAJOR MEDICAL; KAPLAN-MEIER ESTIMATE; MASTECTOMY; MEXICO; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; NEOPLASMS, HORMONE-DEPENDENT; PATIENT DROPOUTS; PROGESTERONE; RADIOTHERAPY, ADJUVANT; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84861657874     PISSN: 00348376     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Dirección General de Epidemiología, Secretaría de Salud. RHNM 2002.
2. Palacio-Mejía LS, Lazcano-Ponce E, Allen-Leigh B, et al. Diferencias regionales en la mortalidad por cáncer de mama y cérvix en México entre 1979 y 2006. Sal Púb Méx 2009; 51(Supl. 2): S208-S219.
3. Porter PL. Global trends in breast cancer incidence and mortality. Sal Pub Mex 2009; 51(Supl. 2): S141-S146.
4. Schwartsmann G. Breast cancer in South America: challenges to improve early detection and medical management of a public health problem. J Clin Oncol 2001; (Suppl. 18): 118S-124S. (Pubitemid 32880094)
5. Adebamowo CA, Adekunle OO. Case controlled study of the epidemiological risk factor for breast cancer in Nigeria. Br J Surg 1999; 86: 665-8. (Pubitemid 29248362)
6. Lozano-Ascencio R, Gómez-Dantés H, Lewis S, et al. Tendencies del cáncer de mama en América Latina y El Caribe. Sal Púb Méx 2009; 51(Supl. 2): S147-S156.
7. Knaul FM, Nigenda G, Lozano R, et al. Cáncer de mama en México: una prioridad apremiante. Sal Púb Méx 2009; 51(Supl. 2): S335-S344.
8. Educational Book 2004, 40th Annual Meeting ASCO.
9. El Saghir NS, Eniu A, Carlson RW, et al. Locally advanced breast cancer treatment guideline implementation with particular attention to low-and middle-income countries. Cancer 2008; 103 (Suppl. 8): 2315-24.
10. Hennessy BT, Hortobagyi GN, Rouzier R, et al. Outcome after pathologic complete eradication of cytologically proven breast cancer axillary node metastases following primary chemotherapy. J Clin Oncol 2005; 23: 9304-11.
11. Wolmark N, Wang J, Mamounas E, et al. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B18. J Natl Cancer Inst Monogr 2001; 30: 96-102.
12. Guarneri V, Broglio K, Kau SW, et al. Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. J Clin Oncol 2006; 24: 1037-44. (Pubitemid 46638799)
13. Buzdar A, et al. Proc ASCO 2004; 23: 7 (Abstract 520).
14. Hurley J, Doliny Ph, Reis I, et al. Docetaxel, cisplatin and trastuzumab as a primary systemic therapy for human epidermal growth factor receptor 2-positive locally advanced breast cancer. J Clin Oncol 2006; 24: 1831-8. (Pubitemid 46638980)
15. Peto R. The worldwide overview: new results for systemic adjuvant therapies. Plenary Lecture. 30th Annual San Antonio Breast Cancer Symposium San Antonio, TX. 2007.
16. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177-82. (Pubitemid 17231334)
17. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989; 244: 707-14.
18. Kwan ML, Kushi LH, Weltizien E, et al. Epidemiology of breast cancer subtypes in two prospective cohort studies of breast cancer survivors. Breast Cancer Research 2009; 11: R31 [Doi:10.1186/bcr2261].
19. Dent R, Trudeau M, Pritchard KI, et al. Triple negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 2007; 13: 4429-34. (Pubitemid 47219710)
20. Carey L, Perau CM, Livasy CA, et al. Race, breast cancer subtypes and survival in the Carolina breast cancer study. JAMA 2006; 295: 2492-502. (Pubitemid 43854964)
21. Abdullah N, Hisham, Cheng-Har Y. Overview of breast cancer in Malaysian women: a problem with late diagnosis. Asian J Surg 2004;2 7: 130-3.
22. Sant M, Allemani C, Berrino F, et al. Breast cancer survival en Europe and the United States. A population based study. Cancer 2004; 100: 715-22. (Pubitemid 38176848)
23. Mohar A, Bargalló E, Ramírez MT, Lara F, Beltrán-Ortega A. Recursos disponibles para el tratamiento del cáncer de mama en México. Sal Púb Méx 2009; 51 (Supl. 2): S263-S269.
24. Martínez-Montañez OG, Uribe-Zúñiga P, Hernández-Ávila M. Políticas públicas para la detección del cáncer de mama en México. Sal Púb Méx 2009; 51(Supl. 2): 350-60.
25. Brandan ME, Villaseñor Y. Detección del cáncer de mama: estado de la mamografía en México. Cancerología 2006; 1: 147-62.
26. Hortobagyi G, De la Garza Salazar J, Pritchard K, et al. The global breast cancer burden: variations in epidemiology and survival. Clin Breast Cancer 2005; 6: 391-401. (Pubitemid 43078894)
27. Davidson NE, Morrow M. An assessment of neoadjuvant systemic therapy for breast cancer. J Natl Cancer Inst 2005; 97: 159-61. (Pubitemid 40277358)
28. Veronesi U, Bonadonna G, Zurrida S, et al. Conservation surgery after primary chemotherapy in large carcinomas of the breast. Ann Surg 1995; 222: 612-8.